FindTrial
Sign In

Dosing optimization of letermovir in allogeneic hematopoietic stem cell transplantation by population pharmacokinetic and pharmacodynamic study

Dosing optimization of letermovir in allogeneic hematopoietic stem cell transplantation by population pharmacokinetic and pharmacodynamic study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096057
Enrollment
Unknown
Registered
2025-01-16
Start date
2024-09-10
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic hematopoietic stem cell transplantation recipients

Interventions

Letermovir group:NA

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Allogeneic hematopoietic stem cell transplant recipients; 2. Recipient cytomegalovirus serology positive; 3. Oral letermovir prophylaxis; 4. Collection of at least one clinical blood sample post-treatment;

Exclusion criteria

Exclusion criteria: 1. Medical records or test results cannot be fully obtained; 2. Patients who refuse to give informed consent;

Design outcomes

Primary

MeasureTime frame
Letermovir blood concentration;—

Countries

China

Contacts

Public ContactDong Yalin

The First Affiliated Hospital of Xi'an Jiaotong University

dongyalin@mail.xjtu.edu.cn+86 29 85323241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026